应对。
Tackling .
作者信息
Granata Guido, Taglietti Fabrizio, Petrosillo Nicola
机构信息
Clinical and Research Department for Infectious Diseases, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.
Infection Prevention & Control/Infectious Disease Service, Fondazione Policlinico Universitario Campus Bio-Medico, 00127 Rome, Italy.
出版信息
J Clin Med. 2023 Aug 8;12(16):5168. doi: 10.3390/jcm12165168.
Abstract
Globally, multidrug-resistant (MDR) bacteria represent a menace to public health [...].
摘要
在全球范围内，多重耐药（MDR）细菌对公众健康构成威胁[...]。
相似文献
1
Tackling .应对。
J Clin Med. 2023 Aug 8;12(16):5168. doi: 10.3390/jcm12165168.
2
Virulence Potential and Treatment Options of Multidrug-Resistant (MDR) .多重耐药（MDR）的毒力潜能及治疗选择
Microorganisms. 2021 Oct 6;9(10):2104. doi: 10.3390/microorganisms9102104.
3
Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial.作为替加环素评估与监测试验的一部分，2004年至2014年期间替加环素对多重耐药革兰氏阴性病原菌活性的全球评估
mSphere. 2017 Jan 18;2(1). doi: 10.1128/mSphere.00310-16. eCollection 2017 Jan-Feb.
4
Burden of Multidrug-Resistant Infection in Hospitalized Patients in a Tertiary Care Hospital of Nepal.尼泊尔一家三级护理医院住院患者多重耐药感染的负担
Infect Drug Resist. 2020 Mar 3;13:725-732. doi: 10.2147/IDR.S239514. eCollection 2020.
5
Molecular epidemiology of multidrug-resistant Acinetobacter baumannii isolates in a university hospital in Nepal reveals the emergence of a novel epidemic clonal lineage.尼泊尔一家大学医院多重耐药鲍曼不动杆菌分离株的分子流行病学研究显示出一种新型流行克隆谱系的出现。
Int J Antimicrob Agents. 2015 Nov;46(5):526-31. doi: 10.1016/j.ijantimicag.2015.07.012. Epub 2015 Aug 28.
6
Genotypic Patterns of Multidrug-Resistant : A Systematic Review.多重耐药的基因型模式：一项系统综述
Adv Biomed Res. 2023 Mar 21;12:56. doi: 10.4103/abr.abr_434_22. eCollection 2023.
7
Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolates from four German University Hospitals, 2002-2006.2002-2006 年德国四所大学医院分离的鲍曼不动杆菌对多种药物耐药性的发生率不断增加。
Infection. 2010 Feb;38(1):47-51. doi: 10.1007/s15010-009-9225-x. Epub 2010 Jan 27.
8
Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii Pulmonary Infection.挽救四环素类抗生素治疗多重耐药鲍曼不动杆菌肺部感染。
mBio. 2022 Feb 22;13(1):e0351721. doi: 10.1128/mbio.03517-21. Epub 2022 Jan 11.
9
Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit.多重耐药和广泛耐药鲍曼不动杆菌医院感染与高死亡率相关：儿科重症监护病房的回顾性研究。
BMC Infect Dis. 2020 Aug 12;20(1):597. doi: 10.1186/s12879-020-05321-y.
10
New Shuttle Vectors for Real-Time Gene Expression Analysis in Multidrug-Resistant Acinetobacter Species: and Responses to Environmental Stressors.新型穿梭载体用于多重耐药不动杆菌属实时基因表达分析： 和对环境应激因子的响应。
Appl Environ Microbiol. 2019 Aug 29;85(18). doi: 10.1128/AEM.01334-19. Print 2019 Sep 15.
引用本文的文献
1
Characterization of phage HZY2308 against Acinetobacter baumannii and identification of phage-resistant bacteria.噬菌体 HZY2308 对鲍曼不动杆菌的特性分析及耐药菌的鉴定。
Virol J. 2024 Nov 7;21(1):283. doi: 10.1186/s12985-024-02556-y.
本文引用的文献
1
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).舒巴坦-他唑巴坦与多黏菌素治疗鲍曼不动杆菌-醋酸钙不动杆菌复合体引起的严重感染患者的疗效和安全性：一项多中心、随机、阳性药物对照、3 期、非劣效性临床研究（ATTACK）。
Lancet Infect Dis. 2023 Sep;23(9):1072-1084. doi: 10.1016/S1473-3099(23)00184-6. Epub 2023 May 11.
2
Catheter-Associated Urinary Tract Infections, Bacteremia, and Infection Control Interventions in a Hospital: A Six-Year Time-Series Study.医院中导管相关尿路感染、菌血症及感染控制干预措施：一项为期六年的时间序列研究
J Clin Med. 2022 Sep 15;11(18):5418. doi: 10.3390/jcm11185418.
3
The Burden of Carbapenem-Resistant in ICU COVID-19 Patients: A Regional Experience.重症监护病房新冠肺炎患者中耐碳青霉烯类感染的负担：一项地区经验
J Clin Med. 2022 Sep 2;11(17):5208. doi: 10.3390/jcm11175208.
4
Frequency, Etiology, Mortality, Cost, and Prevention of Respiratory Tract Infections-Prospective, One Center Study.呼吸道感染的发病率、病因、死亡率、成本及预防——前瞻性单中心研究
J Clin Med. 2022 Jun 29;11(13):3764. doi: 10.3390/jcm11133764.
5
Durlobactam in the Treatment of Multidrug-Resistant Infections: A Systematic Review.杜洛巴坦治疗多重耐药感染的系统评价
J Clin Med. 2022 Jun 7;11(12):3258. doi: 10.3390/jcm11123258.
6
Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant Infection: A Meta-Analysis.多黏菌素单药治疗与多黏菌素联合美罗培南治疗多重耐药感染的Meta分析
J Clin Med. 2022 Jun 6;11(11):3239. doi: 10.3390/jcm11113239.
7
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.头孢地尔罗或最佳现有治疗方案治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染的疗效和安全性（CREDIBLE-CR）：一项随机、开放标签、多中心、以病原体为重点、描述性的 3 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
8
Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia.医院获得性细菌性肺炎的流行病学、治疗与预防
J Clin Med. 2020 Jan 19;9(1):275. doi: 10.3390/jcm9010275.
9
Is Polymicrobial Bacteremia an Independent Risk Factor for Mortality in Bacteremia?polymicrobial菌血症是菌血症患者死亡的独立危险因素吗？
J Clin Med. 2020 Jan 6;9(1):153. doi: 10.3390/jcm9010153.
Zotero 插件